Policy | July 11, 2025
EU launches strategies to strengthen crisis readiness and health security
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
